Potential of solid lipid nanoparticles in brain targeting

Formulation and Evaluation of Therapeutic Potential of Nanoemulsion of a Blend of Antimicrobial Oils

“…The size range achieved has been reported to enhance the activity of antimicrobial agents. 31,32 Nanostructures are achieved when they are less than 500 nm. The more the number of structures with larger sizes, the more unstable the formulation becomes.…”

Brain Drug Delivery Systems for Neurodegenerative Disorders

“…The important factors for a delivery system to be effective are high drug loading, physical and chemical stability and a low incidence of toxicity of the carrier used. Furthermore, the in vivo fate of the carrier, the chances of scaling up the producing process and the overall cost are other considerations to be kept in mind before deciding on the suitability of the system [5]. Among DDS, polymeric (Fig 1 and 2) or lipidic (Fig 3) micro-and nanoparticles, liposomes (Fig 4), and polymeric micelles ( Fig 5) seem to be the most effective in providing neuroprotection and facilitating the delivery of drugs and small molecules to the brain [6].…”

“…Several systems such as liposomes (Fig 4), polymeric nanoparticles (Fig 2), polymeric nanogels, solid lipid nanoparticles (Fig 3) and polymeric micelles (Fig 5) have been investigated in systemic delivery [5,[11][12][13]. Up to now, liposomes and polymeric nanoparticles are most generally exploited for brain applications [14].…”

Nanomaterials in controlled drug release

“…Various nanoparticles since then were designed and developed, including poly(ethylene oxide)-poly(L-lactic acid)/poly(b-benzyl-L-aspartate), poly(lactideco-glycolide)-[(propylene oxide)-poly(ethylene oxide)], polyphosphazene derivatives, poly(ethylene glycol)-coated nanospheres, azidothymidin (AZT)/dideoxycytidine (ddc) nanoparticles, poly (isobutylcynoacrylate) nanocapsules, poly(g-benzyl-L-glutamate)/poly(ethylene oxide), chitosan-poly(ethylene oxide) nanoparticles, methotrexate-o-carboxymethylate chitosan, solid lipid nanoparticles (SLNs), and so on (Blasi et al 2009;Caruso et al 2010;Chekhonin et al 2009;Fonseca et al 2009;Gilmore et al 2008;Graf et al 2009;Huynh et al 2009;Jatariu et al 2009;Kaur et al 2008;Khalil and Mainardes 2009;Ljubimova et al 2008;Mistry et al 2009b;Modi et al 2010;Namdeo et al 2008;Shilpi et al 2007;Tosi et al 2008;Wong et al 2010). Further to these polymer nanoparticles, there are metal-based, lipid-based, and biological nanoparticles.…”